General Announcement::IX PARTICIPATES IN STUDY: WAFERMINE FOR TREATMENT OF BREAKTHROUGH PAIN IN ADVANCED CANCER PATIENTS

Issuer & Securities

Issuer/ Manager
IX BIOPHARMA LTD.
Securities
IX BIOPHARMA LTD. - SG1BD9000009 - 42C
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
15-Jun-2021 07:26:00
Status
New
Announcement Sub Title
IX PARTICIPATES IN STUDY: WAFERMINE FOR TREATMENT OF BREAKTHROUGH PAIN IN ADVANCED CANCER PATIENTS
Announcement Reference
SG210615OTHR7J33
Submitted By (Co./ Ind. Name)
Lee Wei Hsiung
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please refer to the attachment.

Attachments

Press Release - Wafermine Breakthrough Cancer Pain Study.pdf
Total size =615K